Buradasınız

Comparative adverse effects of aceclofenac and celecoxib on liver of wistar albino rats

Journal Name:

Publication Year:

Abstract (2. Language): 
Introduction: NSAIDS are most widely used analgesics with established gastrointestinal side effects which may even lead to death of the patient when used regularly. Many studies are suggestive of additional toxicities including cardiovascular and hepatocellular toxicities. The present study was planned to compare the hepatotoxic effects of Aceclofenac and Celecoxib on Wistar albino rats. Methods: The animals were administered with the drugs intraperitoneally for a period of 30 days. After the study period, the rats were sacrificed and blood samples and liver were collected. The liver was stained with H/E stain and observed under light microscope for histopathological changes. The levels of serum AST and ALT were measured. Observation: It was observed that the histological changes were more pronounced in case of animals treated with Celecoxib than those treated with Aceclofenac. There was increase in the AST and ALT levels in both the experimental animal groups when compared to control group but the increase is not significant. Result: The histological changes are more pronounced in case of animals treated with Celecoxib than those treated with Aceclofenac. Conclusion: It is inferred that the chronic intake or utilization of higher doses of Celecoxib and Aceclofenac will lead to fatty liver changes, hepatitis and other hepatic complications and Celecoxib is more hepatotoxic than Aceclofenac in therapeutic doses.
303
307

REFERENCES

References: 

1. Needleman P, Isakson PC. The Discovery And Function Of Cox-2. J. Rheumatol, 1997; 24 (suppl
49): 6-8.
2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Theodore P, Whelton A. Gastrointestinal
toxicity with Celecoxib vs Non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid
arthritis. JAMA, 2010; 284(10): 1247-1255.
3. Masferrer JL, Zweifel BS, Mamm PT. Selection inhibition of inducible COX-2 in vivo is antiinflammatory
and non-ulcerogenic. Proc. Natl. Acad. Sci. USA, 1994; 91: 3228-3232.
4. Seibert K, Zan Y, Leahy K. Pharmacological and biochemical demonstration of the role of
cyclooxygenase-2 in inflammation and pain. Proc. Natl. Acad. Sci. USA, 1994; 91: 12013-12017.
5. Warner TD, Giulian F, Voluovic I. Non-steroidal drug selectivities. Natl. Acad. Sci. USA, 1999
96: 7563-7568.
6. Simon LS. Biologic effects of non-steroidal anti-inflammatory drugs. Curr. Opin. Rheum, 1997; 9:
178-182.
7. Lewis JH, Zimmerman HJ. NSAID hepatotoxicity. Con temp. OB/GYN, 2006; November 81-101.
8. Zimmerman HJ. Update of hepatotoxicity due to classes of drugs common use: non steroidal
drugs, anti-inflammatory drugs, antibiotics, antihypertensive and cardiac and psychotropic agents.
Semin. Liver Dis, 1996; 10: 322-338.
9. Merlani G, Fox M, Oehen HP. Fatal hepatotoxicity secondary to Nimesulide. Eur. J. Clin.
Pharmacol, 2001; 57: 321-326.
10. Algeria P, Lebre L, chagas C. Celecoxib induced cholestatic hepatotoxicity in a patient with
cirrhosis. Ann Intern Med, 2002; 137: 75.
11. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel
cyclooxygenase-2 inhibitor Celecoxib. AM. J. Ther, 2007 7: 153-158.
12. Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient
taking Celecoxib. Post. Grad. Med. J, 2001; 77: 548-550.
13. O’beirne JP, Cairns SR. Cholestatic hepatitis in association with Celecoxib. B.M.J, 2001; 323
(7303): 23.
14. Burdan F, Szumito, Klepacz R. Gastrointestinal and hepatic toxicity of selective and non-selective
cyclo-oxygenase-2 inhibitors in pregnant and non-pregnant rats. Pharmacological Research, 2004;
50: 533-543.
15. Niranjan R, Manik P, Srivastava AK, Palit G, Natu SM. Comparative adverse effects of COX-1
and COX-2 inhibitors in rat liver: an experimental study. J. Ant. Soc. India, 2010; 59 (2):182-186.

Thank you for copying data from http://www.arastirmax.com